Managing residual risk in patients receiving statin therapy

Brett H Forge
Med J Aust 2011; 194 (1): . || doi: 10.5694/j.1326-5377.2011.tb04159.x
Published online: 3 January 2011

To the Editor: I would like to endorse the letter by Montgomery1 questioning the efficacy of ezetimibe. As yet there are no data to support its use in clinical trials using carotid intima media thickness (CIMT) as a measure of treatment effectiveness, and there is also some evidence to suggest it could be harmful.

  • Brett H Forge

  • West Gippsland Hospital, Warragul, VIC.



remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.